Top Medical News
15 hours ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Low levels of glucose at bedtime of the previous day and fasting glucose appear to be reasonably predictive of nocturnal asymptomatic, serious, clinically important hypoglycaemia in type 1 diabetes (T1D) patients taking insulin degludec (IDeg), a new study has found.
Jairia Dela Cruz, Yesterday
Patients who have undergone weight-loss surgery may sometimes have to return for revision, which helps improve outcomes associated with obesity, such as diabetes and hypertension, according to a meta-analysis.
2 days ago
Maternal and paternal histories of diabetes have different effects on offspring risk of insulin secretion and resistance, and diabetes, a new study has found.
2 days ago
There appear to be minimal differences between generic and branded exenatide when used as an add-on therapy in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on monotherapy or combination therapy of metformin and insulin secretagogues, a study has found.
4 days ago
Among women with gestational diabetes mellitus (GDM), increased severity of sleep-disordered breathing is associated with poor glycaemic control during the night and early morning, a study has found.
4 days ago
Higher consumption of dietary fibres (DF), particularly soluble (SF) and insoluble fibres (IF) from fruits, reduces the risk of several chronic diseases and mortality, suggests a study.
Special Reports
09 Jul 2020
In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.
29 Jun 2020
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.
Elvira Manzano, 28 Jun 2020
Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.
08 Jun 2020
In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.
11 May 2020
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.
Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

08 Apr 2020
This is the first issue in a series of five articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data release. This issue brings insight to the trial’s background, study design and key results.
Conference Reports
Roshini Claire Anthony, 28 Jul 2020

About one-quarter of the calories consumed by children and adolescents may be acquired from empty calories, according to a US-based study presented at Nutrition 2020 Live Online.

Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Elvira Manzano, 28 Jul 2020
Women with a history of gestational diabetes were 50 percent more likely to have a short interval between pregnancies compared to women without the condition, suggests a new study.
Roshini Claire Anthony, 23 Jul 2020

Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.

Roshini Claire Anthony, 18 Jul 2020

The concurrent occurrence of diabesity and COVID-19 may lead to more severe disease due to the latter, according to a presentation at the Opening Session of ENDO Online.

Elaine Soliven, 18 Jul 2020

The use of insulin detemir among women with pre-existing diabetes was not associated with an increased risk of negative pregnancy outcomes, such as major congenital malformations and perinatal or neonatal deaths, compared with other basal insulins, according to the EVOLVE* study.

Roshini Claire Anthony, 17 Jul 2020

Icosapent ethyl may reduce the risk of cardiovascular (CV) events in patients with diabetes mellitus (DM) taking statins, according to findings of REDUCE-IT DIABETES presented at ADA 2020.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download